Life Science Investing Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Juggernaut Further Increases Oversubscribed Financing to $9,557,000 due to Tremendous Strong Demand from Institutions and Accredited Investors
CoTec Holdings Corp. To Commence Expansion Drilling Program And Secure A Salter Techology Bulk Sample At The Lac Jeannine Property
